Zacks Research Has Positive Outlook of Prothena Q1 Earnings

Prothena Co. plc (NASDAQ:PRTA) – Equities researchers at Zacks Research upped their Q1 2025 EPS estimates for Prothena in a research note issued on Wednesday, March 12th. Zacks Research analyst E. Bagri now forecasts that the biotechnology company will earn ($1.06) per share for the quarter, up from their previous estimate of ($1.33). The consensus estimate for Prothena’s current full-year earnings is ($4.04) per share. Zacks Research also issued estimates for Prothena’s Q2 2025 earnings at ($1.11) EPS, Q3 2025 earnings at ($1.11) EPS, Q4 2025 earnings at ($0.48) EPS, FY2025 earnings at ($3.76) EPS, Q1 2026 earnings at ($1.27) EPS, Q2 2026 earnings at ($1.18) EPS, Q3 2026 earnings at ($1.28) EPS, Q4 2026 earnings at ($0.31) EPS and FY2026 earnings at ($4.04) EPS.

Prothena (NASDAQ:PRTA) last released its quarterly earnings data on Thursday, February 20th. The biotechnology company reported ($1.08) earnings per share for the quarter, missing the consensus estimate of ($1.02) by ($0.06). Prothena had a negative net margin of 90.50% and a negative return on equity of 22.67%. The company had revenue of $2.12 million for the quarter, compared to analysts’ expectations of $7.53 million.

Other research analysts have also recently issued reports about the stock. HC Wainwright reissued a “buy” rating and set a $48.00 price objective on shares of Prothena in a report on Friday, February 21st. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Prothena in a report on Friday, February 21st. Bank of America reduced their target price on shares of Prothena from $26.00 to $22.00 and set a “neutral” rating for the company in a report on Thursday, December 19th. Piper Sandler upped their target price on shares of Prothena from $94.00 to $110.00 and gave the company an “overweight” rating in a report on Wednesday, February 26th. Finally, Oppenheimer upped their target price on shares of Prothena from $58.00 to $62.00 and gave the company an “outperform” rating in a report on Friday, February 7th. Three analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $55.00.

Prothena Stock Down 2.3 %

PRTA opened at $13.74 on Monday. The firm has a 50 day moving average price of $14.40 and a 200-day moving average price of $16.10. Prothena has a twelve month low of $11.70 and a twelve month high of $26.75. The stock has a market capitalization of $739.58 million, a price-to-earnings ratio of -5.97 and a beta of -0.02.

Hedge Funds Weigh In On Prothena

A number of hedge funds have recently modified their holdings of the company. Orion Portfolio Solutions LLC boosted its position in shares of Prothena by 4.4% in the third quarter. Orion Portfolio Solutions LLC now owns 17,531 shares of the biotechnology company’s stock worth $293,000 after purchasing an additional 739 shares during the period. Virtus ETF Advisers LLC boosted its position in shares of Prothena by 19.3% in the fourth quarter. Virtus ETF Advisers LLC now owns 5,148 shares of the biotechnology company’s stock worth $71,000 after purchasing an additional 833 shares during the period. China Universal Asset Management Co. Ltd. boosted its position in shares of Prothena by 10.3% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 11,409 shares of the biotechnology company’s stock worth $158,000 after purchasing an additional 1,065 shares during the period. Rhumbline Advisers boosted its position in shares of Prothena by 1.8% in the fourth quarter. Rhumbline Advisers now owns 67,115 shares of the biotechnology company’s stock worth $930,000 after purchasing an additional 1,175 shares during the period. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in shares of Prothena by 6.0% in the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 27,269 shares of the biotechnology company’s stock worth $381,000 after purchasing an additional 1,551 shares during the period. 97.08% of the stock is currently owned by institutional investors.

Prothena Company Profile

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson’s disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer’s disease.